1 Vancouver Spine Program, Vancouver General Hospital , Vancouver, British Columbia, Canada .
2 Rick Hansen Institute , Blusson Spinal Cord Center, Vancouver, British Columbia, Canada .
J Neurotrauma. 2018 Feb 1;35(3):435-445. doi: 10.1089/neu.2017.5357. Epub 2017 Nov 6.
Biomarkers of acute human spinal cord injury (SCI) could provide a more objective measure of spinal cord damage and a better predictor of neurological outcome than current standardized neurological assessments. In SCI, there is growing interest in establishing biomarkers from cerebrospinal fluid (CSF) and from magnetic resonance imaging (MRI). Here, we compared the ability of CSF and MRI biomarkers to classify injury severity and predict neurological recovery in a cohort of acute cervical SCI patients. CSF samples and MRI scans from 36 acute cervical SCI patients were examined. From the CSF samples taken 24 h post-injury, the concentrations of inflammatory cytokines (interleukin [IL]-6, IL-8, monocyte chemotactic protein-1), and structural proteins (tau, glial fibrillary acidic protein, and S100β) were measured. From the pre-operative MRI scans, we measured intramedullary lesion length, hematoma length, hematoma extent, CSF effacement, cord expansion, and maximal spinal cord compression. Baseline and 6-month post-injury assessments of American Spine Injury Association Impairment Scale (AIS) grade and motor score were conducted. Both MRI measures and CSF biomarker levels were found to correlate with baseline injury grade, and in combination they provided a stronger model for classifying baseline AIS grade than CSF or MRI biomarkers alone. For predicting neurological recovery, the inflammatory CSF biomarkers best predicted AIS grade conversion, whereas structural biomarker levels best predicted motor score improvement. A logistic regression model utilizing CSF biomarkers alone had a 91.2% accuracy at predicting AIS conversion, and was not strengthened by adding MRI features or even knowledge of the baseline AIS grade. In a direct comparison of MRI and CSF biomarkers, the CSF biomarkers discriminate better between different injury severities, and are stronger predictors of neurological recovery in terms of AIS grade and motor score improvement. These findings demonstrate the utility of measuring the acute biological responses to SCI as biomarkers of injury severity and neurological prognosis.
生物标志物可用于急性人类脊髓损伤(SCI),与目前的标准化神经评估相比,它能更客观地衡量脊髓损伤程度,并更好地预测神经预后。在 SCI 中,人们越来越有兴趣从脑脊液(CSF)和磁共振成像(MRI)中建立生物标志物。在这里,我们比较了 CSF 和 MRI 生物标志物在急性颈段 SCI 患者中区分损伤严重程度和预测神经恢复的能力。对 36 例急性颈段 SCI 患者的 CSF 样本和 MRI 扫描进行了检查。从损伤后 24 小时采集的 CSF 样本中,测量了炎症细胞因子(白细胞介素 [IL]-6、IL-8、单核细胞趋化蛋白-1)和结构蛋白(tau、胶质纤维酸性蛋白、S100β)的浓度。从术前 MRI 扫描中,我们测量了脊髓内病变长度、血肿长度、血肿范围、CSF 消失、脊髓扩张和最大脊髓压迫。进行了基线和 6 个月时的美国脊柱损伤协会损伤量表(AIS)分级和运动评分评估。发现 MRI 测量值和 CSF 生物标志物水平均与基线损伤分级相关,并且与 CSF 或 MRI 生物标志物单独使用相比,联合使用可为分级基线 AIS 分级提供更强的模型。在预测神经恢复方面,炎症性 CSF 生物标志物最能预测 AIS 分级转换,而结构生物标志物水平最能预测运动评分改善。使用 CSF 生物标志物的逻辑回归模型对 AIS 转换的预测准确率为 91.2%,并且通过添加 MRI 特征甚至基线 AIS 分级的知识,其准确性并未得到提高。在 MRI 和 CSF 生物标志物的直接比较中,CSF 生物标志物在区分不同损伤严重程度方面表现更好,并且在 AIS 分级和运动评分改善方面是更强的神经预后预测因子。这些发现证明了测量急性 SCI 生物反应作为损伤严重程度和神经预后生物标志物的实用性。